$100 million capital raising done and dusted, page-2

From where I sit the CR has done minimal damage at this point in time, admittedly it is mixed up in EOFY trading which again from where I sit
clouds a lot of trading patterns...note: in this regard EOFY is not current in Nasdaq considerations...Anyway in Aus, we have dilution that doesn't appear
to be overconcerning buyers and the consequence of this we have a n=750 registrational trial at the pointy end of where a drug needs to be
to get approval for commercialisation...We are well positioned to give EFTI a chance to prove itself, that's what it's all about...